TheStreet upgraded shares of Nevro Corp. (NYSE:NVRO) from a d+ rating to a c- rating in a report released on Monday.

NVRO has been the topic of a number of other reports. Zacks Investment Research raised shares of Nevro Corp. from a sell rating to a hold rating in a research report on Tuesday, October 24th. BMO Capital Markets reaffirmed a buy rating and set a $106.00 price objective on shares of Nevro Corp. in a research report on Friday, September 1st. BidaskClub raised shares of Nevro Corp. from a sell rating to a hold rating in a research report on Sunday, July 16th. Canaccord Genuity reaffirmed a buy rating and set a $120.00 price objective on shares of Nevro Corp. in a research report on Sunday, October 8th. Finally, Leerink Swann reaffirmed an outperform rating and set a $110.00 price objective (up from $105.00) on shares of Nevro Corp. in a research report on Tuesday. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. Nevro Corp. currently has a consensus rating of Hold and a consensus target price of $100.00.

Nevro Corp. (NYSE NVRO) opened at $77.49 on Monday. Nevro Corp. has a 1 year low of $65.82 and a 1 year high of $99.63. The company has a debt-to-equity ratio of 0.59, a current ratio of 8.78 and a quick ratio of 8.73.

Nevro Corp. (NYSE:NVRO) last announced its quarterly earnings data on Monday, November 6th. The medical equipment provider reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.02. Nevro Corp. had a negative net margin of 14.09% and a negative return on equity of 17.27%. The firm had revenue of $82.26 million for the quarter, compared to the consensus estimate of $80.50 million. During the same period in the previous year, the firm posted ($0.14) earnings per share. The firm’s revenue was up 35.0% on a year-over-year basis. sell-side analysts expect that Nevro Corp. will post -1.2 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Nevro Corp. (NVRO) Upgraded by TheStreet to “C-“” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/11/10/nevro-corp-nvro-upgraded-by-thestreet-to-c.html.

In other Nevro Corp. news, Director Michael F. Demane sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $93.50, for a total value of $467,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew H. Galligan sold 7,000 shares of the business’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $82.31, for a total transaction of $576,170.00. The disclosure for this sale can be found here. Insiders sold 290,907 shares of company stock valued at $24,670,065 over the last three months. Insiders own 12.10% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. boosted its holdings in shares of Nevro Corp. by 17.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,432 shares of the medical equipment provider’s stock worth $181,000 after buying an additional 358 shares during the period. PNC Financial Services Group Inc. bought a new stake in shares of Nevro Corp. during the 2nd quarter worth $190,000. US Bancorp DE boosted its holdings in shares of Nevro Corp. by 412.4% during the 2nd quarter. US Bancorp DE now owns 2,608 shares of the medical equipment provider’s stock worth $194,000 after buying an additional 2,099 shares during the period. Inspirion Wealth Advisors LLC bought a new stake in shares of Nevro Corp. during the 2nd quarter worth $205,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Nevro Corp. during the 3rd quarter worth $211,000.

Nevro Corp. Company Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Analyst Recommendations for Nevro Corp. (NYSE:NVRO)

Receive News & Stock Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related stocks with our FREE daily email newsletter.